TCH346 prevents motor symptoms and loss of striatal FDOPA uptake in bilaterally MPTP-treated primates

TCH346 prevents motor symptoms and loss of striatal FDOPA uptake in bilaterally MPTP-treated primates

The neuroprotective efficacy of the propargylamine TCH346 was studied in the primate model of Parkinson's disease, the bilaterally MPTP-treated monkey. Male rhesus monkeys received 2.5 mg MPTP into the left carotid artery and, 8 weeks later, 1.25 mg MPTP into the right carotid artery. Starting...

Full description

Bibliographic Details
Main Authors: Gerda Andringa, Silvia Eshuis, Elias Perentes, R.Paul Maguire, Daniel Roth, Merdol Ibrahim, Klaus L Leenders, Alexander R Cools
Format: Article
Language:English
Published: Elsevier 2003-11-01
Series:Neurobiology of Disease
Subjects:
Parkinson's disease
MPTP
FDOPA
Propargylamine
TCH346
Primate
Online Access:http://www.sciencedirect.com/science/article/pii/S0969996103001256

Internet

http://www.sciencedirect.com/science/article/pii/S0969996103001256

Similar Items